Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arixtra Abdominal Surgery, Acutely Ill Prophylaxis Filings Set For Year-End

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Sanofi-Synthelabo and Organon will kick off their planned label expansion program for the anticoagulant Arixtra with a submission for treatment of venous thromboembolism in the third quarter and subsequent filings for prophylactic use in major abdominal surgery and acutely ill medical patients.

You may also be interested in...



Sanofi/GSK Arixtra Adds DVT, Pulmonary Embolism Treatment Indications

Expanded indications for Sanofi-Synthelabo’s Arixtra come as the firm is preparing to divest the antithrombotic to GlaxoSmithKline.

AstraZeneca Exanta NDA Coming Fourth Quarter; Liver Safety Is Key Issue

AstraZeneca will submit an NDA for its oral anticoagulant Exanta (ximelagatran) for prevention of venous thromboembolism and for stroke prevention in atrial fibrillation patients during the fourth quarter.

AstraZeneca Exanta NDA Coming Fourth Quarter; Liver Safety Is Key Issue

AstraZeneca will submit an NDA for its oral anticoagulant Exanta (ximelagatran) for prevention of venous thromboembolism and for stroke prevention in atrial fibrillation patients during the fourth quarter.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel